Results for the Third Quarter & YTD September 2026

Medistim delivers record third-quarter revenue and record year-to-date EBIT

Medistim ASA today announced its financial results for the third quarter and first nine months of 2026. Sales revenue for the quarter reached a record MNOK 210.0, up 25.9% from MNOK 166.8 (currency-neutral growth of own products of 34.6%), with strong growth across all regions: AMERICAS up 51.7%, APAC up 44.6%, and EMEA up 5.5% on a currency-neutral basis. This brought year-to-date revenue to a record MNOK 613.7, an 18.6% increase. Operating profit (EBIT) for the quarter grew 55.7% to MNOK 63.1, corresponding to a 30.1% EBIT margin, bringing year-to-date EBIT to a record MNOK 185.5, up 20.6%, with a 30.2% margin.

Recurring revenues remained high, accounting for 66.5% of year-to-date sales. The company maintains a solid financial position with a cash balance of MNOK 175.6 and no interest-bearing bank loans at quarter end. Based on the authorization from the General Assembly, the Board has decided on a quarterly dividend of NOK 2.50 per share.

Read the full Q3 2026 financial report and watch the webinar presentation of the results here: Medistim Q3 Results